Malvy D J, Drucker J
Department of Public Health, Faculty of Medicine, University of Tours, France.
Public Health Rev. 1993;21(1-2):41-9.
In France, both inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV) were used until 1983. By that time a new enhanced-potency IPV (eIPV) was licensed and recommended by the French Ministry of Health as the vaccine of choice. Ninety-five per cent of infants have received four doses of eIPV by 24 months of age. No cases of vaccine-associated paralysis among either recipients or those in contact with recipients have been reported since 1983. Only four wild indigenous cases of paralytic poliomyelitis have been reported among unvaccinated children in the past five years and none since 1990. Although paralytic poliomyelitis has been virtually eliminated in France, vaccination programs as well as active surveillance of the community and environment for poliovirus circulation should be reinforced to reach the goal of wild poliovirus eradication.
在法国，直到1983年一直同时使用灭活脊髓灰质炎病毒疫苗（IPV）和口服脊髓灰质炎病毒疫苗（OPV）。到那时，一种新的高效力IPV（eIPV）获得许可，并被法国卫生部推荐为首选疫苗。95%的婴儿在24月龄时已接种4剂eIPV。自1983年以来，未报告接种者或与接种者接触者中发生疫苗相关麻痹病例。在过去五年中，仅在未接种疫苗的儿童中报告了4例野生本土麻痹性脊髓灰质炎病例，自1990年以来则无病例报告。尽管法国实际上已消除麻痹性脊髓灰质炎，但仍应加强疫苗接种计划以及对社区和环境中脊髓灰质炎病毒传播的主动监测，以实现根除野生脊髓灰质炎病毒的目标。
